Compounded Sema Injectable denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied on Medical Necessity — and Why You Can Appeal

A medical-necessity denial from UnitedHealthcare means a UHC clinical reviewer determined that compounded semaglutide injectable does not meet the plan's criteria for medically necessary care — typically because the submitted clinical record did not document the specific conditions (diagnosis severity, prior treatment failures, or clinical indicators) required by UHC's coverage policy. This is not necessarily a statement that the treatment is wrong for you; it is a statement that the documentation submitted did not satisfy UHC's checklist.

Medical-necessity denials are among the most successfully appealed denial types when the clinical record is organized and complete.

## Your Federal Appeal Rights

Under ACA §2719 (non-grandfathered plans) you are entitled to independent external review after exhausting internal appeals. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review and access to the exact criteria and guidelines UHC used. The external-review window is generally open for approximately four months after a final internal denial. If your condition makes delay medically harmful, request an expedited 72-hour review.

## The Concrete Appeal Process

1. Request UHC's medical policy for compounded GLP-1 injectable coverage in writing — you are entitled to it. 2. Compare each criterion in the policy against your existing chart documentation. 3. File a Level 1 internal appeal with a complete, organized clinical package (see below). 4. If denied, escalate to Level 2 or directly to external IRO review, which is binding on UHC.

## Documentation to Gather

• Diagnosis confirmation — office notes with ICD codes, relevant diagnostic test results, and clinical assessments establishing the underlying condition and its severity.
• Clinical severity documentation — chart entries (with dates) that capture the degree of illness, comorbidities, and functional or health impact that makes treatment necessary.
• Prior-treatment history with dates and outcomes — pharmacy records, chart notes, or prescriber attestation for every prior treatment in this therapeutic area: agent name, duration, dose range tried, and why each was stopped (lack of efficacy, adverse effects, contraindication).
• Prescriber medical-necessity letter — a detailed letter from your treating clinician explaining the clinical rationale for this specific therapy, referencing your chart findings, and explaining how your case meets UHC's published criteria. The letter should be patient-specific, not generic.
• Relevant guideline reference — the prescriber may cite the applicable professional society guideline (e.g., the relevant Endocrine Society or Obesity Medicine Association clinical practice guideline) by organization and document name to support that treatment is consistent with the standard of care.

## Criteria-Mapping Structure

Build a table that mirrors UHC's published medical-necessity criteria exactly:

| UHC Coverage Criterion | Chart Evidence That Satisfies It | |---|---| | [Copy each UHC criterion verbatim from the policy] | [Specific chart date, note, test result, or prescriber statement meeting that criterion] |

Submitting a criteria-mapped response prevents UHC from issuing a vague second denial and forces the reviewer to identify precisely which element — if any — is still unmet. Pair this with the prescriber letter and your appeal stands on the strongest possible footing.